EA2192: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2, or PALB2 Mutation
- Title
- APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2, or PALB2 Mutation
- Principal Investigator
- Daboul, Nour
- Phase
- II
- Age Group
- Adult
- Applicable Disease Sites
- Gastrointestinal Cancers
- Participating Institutions
- Camden Clark Medical Center
- Mary Babb Randolph Cancer Center
- United Hospital Center
- Contacts
- Sabrina Rexroad, RN
- Research Nurse
- Email: sabrina.rexroad1@wvumedicine.org
- Layla Tannoury
- Clinical Research Specialist
- Phone: +1 304-424-2585
- Email: layla.tannoury@wvumedicine.org
- Nnennaya Opara
- Clinical Research Specialist
- Phone: +1 681-342-1000
- Email: nnennaya.opara1@wvumedicine.org
- Meg Zafiris
- Research Specialist
- Email: margaret.zafiris@hsc.wvu.edu